Full Press Release Details
Tiziana Life Sciences Ltd
("Tiziana" or "the Company")
Updated Interim Results for the Six Months Ended
London, 29 December 2022 -
Tiziana Life Sciences Ltd ("Tiziana", NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation
approaches to enhance the functionality of Treg-based therapies, today announced its interim results for the six months ended 30 June
Development activity during the first six months
TZLS-501, formerly NI-1201
Highlights post period end:
Intellectual Property
Business Development, and Investor Relations Manager
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical
company developing breakthrough immunomodulation therapies using transformational drug delivery technologies with a focus on its lead
candidate, intranasal foralumab, as a treatment for diseases of the central nervous system (CNS). Tiziana's innovative nasal, oral
and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared
to intravenous (IV) delivery. Tiziana's intranasal foralumab is the only fully human anti-CD3 mAb and has demonstrated a favorable
safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy
has been patented with several applications pending and is expected to allow for broad pipeline applications.